8-K: Carisma Therapeutics Faces Nasdaq Delisting Threat Due to Non-Compliance with Listing Rules

Carisma Therapeutics is at risk of being delisted from the Nasdaq due to its failure to meet minimum market value and share price requirements.

Summary

• Carisma Therapeutics Inc. received notification from Nasdaq on April 10, 2025, that it no longer meets the minimum market value of listed securities (MVLS) requirement of $50.0 million.
• The company also failed to meet the minimum market value of publicly held shares (MVPHS) requirement of $15.0 million.
• Additionally, Carisma Therapeutics was previously notified on January 6, 2025, about its non-compliance with the minimum bid price of $1.00 per share.
• Carisma plans to request a hearing before the Nasdaq Hearings Panel to appeal the delisting, which will temporarily suspend the delisting process.
• However, there is no guarantee that the Panel will grant the company's request for continued listing or that the company will regain compliance with Nasdaq's listing requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and uncertainty surrounding the company's ability to regain compliance with Nasdaq listing requirements.

Positives

• Carisma Therapeutics plans to request a hearing before the Nasdaq Hearings Panel, which will temporarily suspend the delisting process.

Negatives

• Carisma Therapeutics has received notices from Nasdaq for failing to meet the minimum market value of listed securities, minimum market value of publicly held shares, and minimum bid price requirements.
• There is no assurance that the company will regain compliance with Nasdaq listing requirements or that the Panel will grant the company's request for continued listing.

Risks

• The company faces the risk of being delisted from the Nasdaq Stock Market.
• There is uncertainty regarding the outcome of the hearing before the Nasdaq Hearings Panel.
• The company may not be able to regain compliance with Nasdaq's listing requirements.

Future Outlook

The company is considering all available options to regain compliance with the applicable listing criteria, but there can be no assurance that the company will be able to do so.

Management Comments

• The Company plans to timely request a hearing before the Panel, which request will stay any further suspension or delisting action by Nasdaq at least until a hearing is held and any extension that the Panel may grant to the Company following the hearing has expired.

Industry Context

Many biotech companies, especially those in the clinical stage, face challenges in maintaining Nasdaq listing compliance due to market volatility and the inherent risks associated with drug development.

Comparison to Industry Standards

• Companies like Celldex Therapeutics and Ziopharm Oncology have faced similar delisting warnings in the past due to market capitalization issues.
• Regaining compliance often involves strategies such as reverse stock splits, attracting new investments, or demonstrating significant clinical progress.
• Compared to industry peers, Carisma's situation is not unique, but the outcome will depend on its ability to improve its financial position and demonstrate future growth potential.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security.
• The company's ability to raise capital and fund its research and development programs may be negatively impacted.

Next Steps

• Carisma Therapeutics will request a hearing before the Nasdaq Hearings Panel.
• The company will explore options to regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

delisting, Nasdaq, compliance, market value, minimum bid price, Carisma Therapeutics